Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma

Journal of Cutaneous Pathology

Volumn 35, Issue 8, 2008, Pages 722-730

  Chen, Si Yuan ^a,b   Takeuchi, Satoshi ^a   Urabe, Kazunori ^a   Hayashida, Sayaka ^a   Kido, Makiko ^a   Tomoeda, Hiroto ^a   Uchi, Hiroshi ^a   Dainichi, Teruki ^a   Takahara, Masakazu ^a   Shibata, Satoko ^a   Tu, Ya Ting ^b   Furue, Masutaka ^a   Moroi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 3; PARAFFIN; PROTEIN P53; PROTEIN P63; PROTEIN P73; ATF2 PROTEIN, HUMAN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PYOGENIC GRANULOMA; SKIN BLOOD VESSEL; STAINING; VASCULAR TUMOR; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SKIN TUMOR;

ACTIVATING TRANSCRIPTION FACTOR 2; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOMA, PYOGENIC; HEMANGIOSARCOMA; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149191927     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2007.00887.x     Document Type: Article

References (63)

1. Zhao R, Gish K, Murphy M, et al. The transcriptional program following p53 activation. Cold Spring Harb Symp Quant Biol 2000; 65: 475.
2. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2: 740.
3. Karin M, Lin A. NF-kappaB at the crossroads oflife and death. Nat Immunol 2002; 3: 221.
4. Liu F, Green MR. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell 1990; 61: 1217.
5. Falvo JV, Parekh BS, Lin CH, et al. Assembly of a functional beta interferon enhanceosome is dependent on ATF-2-c-jun heterodimer orientation. Mol Cell Biol 2000; 20: 4814.
6. Tsai EY, Jain J, Pesavento PA, et al. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996; 16: 459.
7. Shimizu M, Nomura Y, Suzuki H, et al. Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4. Exp Cell Res 1998; 239: 93.
8. Bhoumik A, Huang TG, Ivanov V, et al. An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest 2002; 110: 643.
9. BhoumikA, GangiL, RonaiZ. Inhibitionofmelanomagrowthand metastasis by ATF2-derived peptides. Cancer Res 2004; 64: 8222.
10. Lewis JS, Vijayanathan V, Thomas TJ, et al. Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2. Oncol Res 2005; 15: 113.
11. Recio JA, Merlin G. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res 2002; 63: 1576.
12. Papassava P, Gorgoulis VG, Papaevangeliou D, et al. Over-expression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res 2004; 64: 8573.
13. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 2000; 25: 496.
14. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88: 435.
15. Garcia R, Yu CL, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997; 8: 1267.
16. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20: 2499.
17. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105.
18. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000; 19: 2489.
19. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive Stat3 activation in malignant human lung epithelial cells. Int J Cancer 1999; 83: 564.
20. Ni Z, Lou W, Leman ES, et al. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth ofprostate cancer cells. Cancer Res 2000; 60: 1225.
21. Burke WM, Jin X, Lin HJ, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001; 20: 7925.
22. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453.
23. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, et al. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 1999; 14: 1.
24. Slichenmyer WJ, Nelson WG, Slebos RJ, et al. Loss of a p53-associated G1 checkpoint does not decreased cell survival following DNA damage. Cancer Res 1993; 53: 4164.
25. Matozaki T, Sakamoto C, Suzuki T, et al. p53 gene mutations in human gastric cancer: Wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res 1992; 52: 4335.
26. Trink B, Okami K, Wu L, et al. A new human p53 homologue. Nat Med 1998; 4: 747.
27. Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p35. Nat Med 1998; 4: 839.
28. Senoo M, Seki N, Ohira M, et al. A second p53-related protein, p73L, with high homology to p73. Biochem Biophys Res Commun 1998; 30: 603.
29. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homologat 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305.
30. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809.
31. Jost CA, Marin MC, Kaelin WG Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389: 191.
32. Han S, Semba S, Abe T, et al. Infrequent somatic mutations of the p73 gene in various human cancers. Eur J Surg Oncol 1999; 25: 194.
33. El-Naggar AK, Lai S, Clayman GL, et al. p73 gene alterations and expression in primary oral and laryngeal squamous carcinoma. Carcinogenesis 2001; 22: 729.
34. Zietz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998; 153: 1425.
35. Naka N, Tomita Y, Nakanishi H, et al. Mutations ofp53 tumor-suppressor gene in angiosarcoma. Int JCancer 1997; 71: 952.
36. Mendenhall WM, Mendenhall CM, Werning JW, et al. Cutaneous angiosarcoma. Am J Clin Oncol 2006; 29: 524.
37. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249.
38. Verheij M, Ruiter GA, Zerp SF, et al. The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis. Radiother Oncol 1998; 47: 225.
39. Ouwens DM, de Ruiter ND, van der Zon GC, et al. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J 2002; 21: 3782.
40. Jacobs WB, Kaplan DR, Miller FD. The p53 family in nervous system development and disease. JNeurochem 2006; 97: 1571.
41. Lim CP, Cao X. Regulation of Stat3 activation by MEKkinase 1. J Biol Chem 2001; 276: 21004.
42. Morton S, Davis RJ, Cohen P. Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett 2004; 572: 177.
43. Newman JR, Keating AE. Comprehensive identification of human bZIP interactions with coiled-coil arrays. Science 2003;300: 2097.
44. Steinmuller L, Cibelli G, Moll JR, et al. Regulation and composition of activator protein 1 (AP-1) transcription factors controlling collagenase and c-Jun promote activities. Biochem J 2001; 360: 599.
45. Kaszubska W, Hooft van Huijsduijnen R, Ghersa P, et al. Cyclic AMP-independent ATF family members interact with NF-kappa B and function in the activation of the E-selecting promoter in response to cytokines. Mol Cell Biol 1993; 13: 7180.
46. Kim SJ, Wagner S, Liu F, et al. The retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2. Nature 1992; 358: 331.
47. Bhoumik A, Ivanov V, Ronai Z. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin Cancer Res 2001; 2: 331.
48. Ma XT, Wang S, Ye YJ, et al. Relationship of Stat3 and its target gene products with malignancy in human colorectal carcinoma. Ai Zheng 2003; 22: 1135.
49. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators oftranscription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002; 62: 3351.
50. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721.
51. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003; 22: 3152.
52. Jackson-Bernitsas DG, Ichikawa H, Takada Y, et al. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 2007; 26: 1385.
53. Conti A, Ageunnouz M, La Torre D, et al. Expression of the tumor necrosis factor receptor-associated factors 1 and 2 and regulation ofthe nuclear factor-kappaB antiapoptotic activity in human gliomas. J Neurosurg 2005; 103: 873.
54. Trauzold A, Roder C, Sipos B, et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J2005;19: 620.
55. Yang A, McKeon F. p63 and p73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000; 3: 199.
56. Yang A, Kaghad M, Caput D, et al. On the shoulders ofgiants: p63, p73 and the rise of p53. Trends Genet 2002; 18: 90.
57. Levrero M, De Laurenzi V, Costanzo A, et al. The p53/p63/ p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113: 1661.
58. Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A 2001; 98:3156.
59. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398: 708.
60. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714.
61. Parsa R, Yang A, McKeon F, et al. Association of p63 in proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999; 113: 1099.
62. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 560.
63. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19: 1438.